A High Risk Group in the Modified National Institutes of Health Consensus Criteria for the Gastrointestinal Stromal Tumor: A Clear Indication of the Adjuvant Imatinib.

Author: Dong Kyung CHANG ¹
Author Information

1. Division of Gastroenterology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. dkchang@skku.edu
Publication Type:Editorial
MeSH: Consensus*; Gastrointestinal Stromal Tumors*; Imatinib Mesylate; National Institutes of Health (U.S.)*
From:Intestinal Research 2014;12(3):176-177
CountryRepublic of Korea
Language:English
Abstract: No abstract available.